This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Amy L. Brotherton, PharmD, AAHIVP, BCIDP
Advertisement
Amy L. Brotherton is a clinical pharmacist specialist in infectious diseases at The Miriam Hospital Infectious Diseases and Immunology Center and an assistant professor of medicine for the Warren Alpert Medical School of Brown University, both in Providence, Rhode Island. She is also a committee member for American College of Clinical Pharmacy HIV Practice Research Network Advocacy Committee. She is also an active member of the Society of Infectious Diseases Pharmacists and of Making a Difference in Infectious Diseases.
Articles by Amy L. Brotherton, PharmD, AAHIVP, BCIDP
Fostemsavir, an HIV-1 attachment inhibitor, is a novel therapeutic option for multidrug-resistant HIV. It represents the first oral agent developed for this indication in over a decade and provides promise for patients with limited remaining treatment options.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Patient With Novel Strain of Avian Influenza Dies
2
DoxyPEP Use Linked to Increased High-Level Tetracycline Resistance in Neisseria gonorrhoeae
3
WHO Reports Declines in TB Incidence and Drug-Resistant TB
4
Atea’s Bemnifosbuvir/Ruzasvir Combination Shows Modeled 7–8 Week Cure Potential for Hepatitis C
5
